


CL-197

Cat. No.:	HY-148191		
CAS No.:	1030595-07-3		
Molecular Formula:	C ₁₂ H ₁₁ F ₂ N ₅ O ₃		
Molecular Weight:	311.24		
Target:	HIV Protease		
Pathway:	Anti-infection; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (321.30 mM; Need ultrasonic)

Concentration	Solvent	Mass	1 mg	5 mg	10 mg
			1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		3.2130 mL	16.0648 mL	32.1295 mL
	5 mM		0.6426 mL	3.2130 mL	6.4259 mL
	10 mM		0.3213 mL	1.6065 mL	3.2130 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.5 mg/mL (8.03 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (8.03 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (8.03 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

CL-197 is an orally active and long-acting purine anti-HIV nucleoside reverse transcriptase inhibitor (NRTI). CL-197 has potential effect on the research of viral, oncological and cerebrovascular diseases^[1]. CL-197 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAC) with molecules containing Azide groups.

REFERENCES

[1]. Hou J, et al. 4'-Ethyne-2'-deoxy-2'- β -fluoro-2'-fluoroadenosine: A Highly Potent and Orally Available Clinical Candidate for the Treatment of HIV-1 Infection. J Med Chem. 2023 Aug 24;66(16):11282-11293.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA